

Lupin Ltd (LUPIN) - Financial and Strategic SWOT Analysis Review

URL:	https://marketpublishers.com/r/L4AC4EF7847EN.html
Date:	September 6, 2017
Pages:	54
Price:	US\$ 125.00
ID:	L4AC4EF7847EN

Lupin Ltd (LUPIN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company's operations and business divisions.
- Corporate strategy – Analyst's summarization of the company's business strategy.
- SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives' employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Lupin Ltd (Lupin) focuses on the development and manufacture of generic and branded formulations, biotechnology products and active pharmaceutical ingredients (APIs). The company has expertise in the areas of cardiovascular, asthma, diabetology, pediatrics, central nervous system, gastro-intestinal, anti-infectives, NSAIDs, anti-TB and cephalosporins. It undertakes extensive research and development of pharmaceuticals for treatment of migraine, gastrointestinal, psoriasis, central nervous system, cardiovascular, tuberculosis, diabetes and inflammation. Lupin develops value-added generic pharmaceuticals based on its platform technologies. The company along with its subsidiaries has manufacturing locations spread across India, USA, Japan, Mexico and Brazil. It offers its products in India, USA, Japan and Other countries. Lupin is headquartered in Mumbai, Maharashtra, India.

Lupin Ltd Key Recent Developments

Aug 21,2017: Lupin receives EIR from US FDA for Aurangabad, April 2017 Inspection

Aug 11,2017: Lupin appoints Manju Deshbandhu Gupta as chairman

Aug 02,2017: Lupin: Appointment of Chairman

Jul 31,2017: Lupin's Aurangabad facility inspection concluded by US FDA

Jul 28,2017: Lupin's Pithampur facility inspection concluded by US FDA without any observations

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Content

SECTION 1 - ABOUT THE COMPANY

Lupin Ltd - Key Facts

Lupin Ltd - Key Employees

Lupin Ltd - Key Employee Biographies

Lupin Ltd - Major Products and Services

Lupin Ltd - History

Lupin Ltd - Company Statement

Lupin Ltd - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Joint Venture

SECTION 2 – COMPANY ANALYSIS

Lupin Ltd - Business Description
Lupin Ltd - Corporate Strategy
Lupin Ltd - SWOT Analysis
SWOT Analysis - Overview
Lupin Ltd - Strengths
Lupin Ltd - Weaknesses
Lupin Ltd - Opportunities
Lupin Ltd - Threats
Lupin Ltd - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY'S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
Lupin Ltd, Recent Deals Summary

SECTION 5 – COMPANY'S RECENT DEVELOPMENTS

Aug 21, 2017: Lupin receives EIR from US FDA for Aurangabad, April 2017 Inspection
Aug 02, 2017: Lupin: Appointment of Chairman
Jul 31, 2017: Lupin's Aurangabad facility inspection concluded by US FDA
Jul 28, 2017: Lupin's Pithampur facility inspection concluded by US FDA without any observations
Jul 21, 2017: Lupin's Goa facility inspection concluded by US FDA without any observations
May 24, 2017: Lupin Announces Quarter IV and Annual Results, FY2017
May 09, 2017: Lupin Announces Opening of its new 100,000 square foot expansion at its Somerset, NJ Manufacturing Site
Apr 28, 2017: Lupin Provides updated on Goa Manufacturing Facility
Mar 03, 2017: Lupin Receives FDA Approval for Generic Suprep Bowel Prep Kit
Feb 09, 2017: Lupin Quarter III Results, FY2017

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Lupin Ltd, Key Facts
Lupin Ltd, Key Employees
Lupin Ltd, Key Employee Biographies
Lupin Ltd, Major Products and Services

Lupin Ltd, History
Lupin Ltd, Other Locations
Lupin Ltd, Subsidiaries
Lupin Ltd, Joint Venture
Lupin Ltd, Key Competitors
Lupin Ltd, Ratios based on current share price
Lupin Ltd, Annual Ratios
Lupin Ltd, Annual Ratios (Cont.1)
Lupin Ltd, Annual Ratios (Cont.2)
Lupin Ltd, Interim Ratios
Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
Lupin Ltd, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

LIST OF FIGURES

Lupin Ltd, Performance Chart (2013 - 2017)
Lupin Ltd, Ratio Charts
Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Lupin Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017

COMPANIES MENTIONED

Sun Pharmaceutical Industries Ltd
Lincon Pharmaceuticals Ltd
Intas Pharmaceuticals Ltd
Dr. Reddy's Laboratories Ltd
Divi's Laboratories Ltd
Cipla Ltd
Abbott India Ltd
Aarti Drugs Ltd

I would like to order:

Product name: Lupin Ltd (LUPIN) - Financial and Strategic SWOT Analysis Review
Product link: <https://marketpublishers.com/r/L4AC4EF7847EN.html>
Product ID: L4AC4EF7847EN
Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service: office@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click 'BUY NOW' button on product page <https://marketpublishers.com/r/L4AC4EF7847EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
E-mail:
Company:
Address:
City:
Zip/Post Code:
Country:
Tel:
Fax:
Your message:

* All fields are required

Customer Signature _____

Please, note that by ordering from MarketPublisher.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms_conditions.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to **+44 20 7900 3970**